Skip to content

    Cancer Health Center

    Font Size
    A
    A
    A

    Acupuncture (PDQ®): Complementary and alternative medicine - Health Professional Information [NCI] - Human / Clinical Studies

    Table 3. Clinical Studies of Acupuncture: Nausea and Vomitinga

    Reference Citation(s) Type of Study Condition Treated No. of Patients: Enrolled; Treated; Controlb Strongest Benefit Reportedc Concurrent Therapyd Level of Evidence Scoree
    CT = controlled trial; EA = electroacupuncture; No. = number; N/V = nausea and vomiting; RCT = randomized controlled trial.
    a Refer to text and theNCI Dictionary of Cancer Termsfor additional information and definition of terms.
    b Number of patients treated plus number of patient controls may not equal number of patients enrolled; number of patients enrolled equals number of patients initially considered by the researcher who conducted a study; number of patients treated equals number of enrolled patients who were given the treatment being studied AND for whom results were reported;historical control subjectsare not included in number of patients enrolled.
    c Strongest evidence reported that the treatment under study has activity or improves the well-being of cancer patients.
    d Concurrent therapy for symptoms treated (not cancer).
    e For information about levels of evidence analysis and an explanation of the level of evidence scores, refer toLevels of Evidence for Human Studies of Cancer Complementary and Alternative Medicine.
    f P< .001, low-frequency EA at classical antiemetic acupuncture points daily versus minimal needling at control points with sham EA versus no adjunct needling.
    g P< .001, EA versus sham EA.
    h P< .001,surface electrodesversus rubber electrodes.
    i P< .00059.
    j P< .02, acupressure versus acupressure at a sham point.
    k P< .05, acupuncture versusnoninvasiveplacebo acupuncture.
    l P< .05, acupressure andacustimulationwrist bands versus no treatment.
    [26] RCT N/V related to high-dose chemotherapy for breast cancer 104; 37; 67 (sham EA or no EA) Less N/V in EA groupf Yes (prochlorperazine, lorazepam, and diphenhydramine) 1iiC
    [24,30,31] RCT N/V from chemotherapy 10; 10 EA; 10 sham EA (crossover study) Significantly less N/V than controlg Yes (metoclopramide) 1iiC
    [27] RCT N/V from chemotherapy 100 (these patients were used more than once because of nature of crossover study); 27surface electrodes; 11 rubber electrodes; 14 crossover study; 24 transcutaneous electrical stimulation 75% achieved considerable benefith Yes (metoclopramide,thiethylperazine, prochlorperazine, cyclizine, lorazepam, and steroid) 1iiC
    [34] RCT N/V from chemotherapy 16 (the same 16 patients treated twice in a crossover study); 16 ondansetron plus transcutaneous electrical stimulation; 16 cross-over treatment ondansetron only Symptom-free patient days: 58.8%i Yes (ondansetron) 1iiC
    [32] RCT N/V from chemotherapy 53 enrolled; 38 completed; 38 acupressure; 38 crossover to acupressure at a sham point 55% reduction in N/Vj Yes (antiemetics) 1iiC
    [36] RCT N/V from high-dose chemotherapy 80; 41 acupuncture; 39 noninvasive placebo acupuncture Nonek Yes (ondansetron) 1iiC
    [35] RCT N/V from chemotherapy 739; 233bilateralacupressure bands and 234transcutaneous electrical stimulationbands; 233 no bands; 39 not evaluable Less N/V in treatment groups than in controll Yes (5-HT3 receptorantagonist,prochlorperazine, and/or others) 1iiC
    [37] RCT N/V from chemotherapy 142; 48 acupuncture + vitamin B6 PC6 point injection; 46 vitamin B6; 48 acupuncture Fewer emesis episodes Yes (diazepam, diphenhydramine, cimetidine, and granisetron) 1iiC
    [41] RCT N/V from chemotherapy 36; 17 acupressure; 19 control Significantly lower N/V Yes (antiemetics) 1iiC
    [40] RCT N/V from radiation 277; 215; 62 Less nausea Yes (antiemetics) 1iiC
    [38] RCT N/V from moderate to highly emetogenic chemotherapy 160; 96; 54 Decreased delayed N/V for acupressure Yes (anthracycline, cyclophosphamide, and an antiemetic) 1iiC
    [25] Nonrandomized controlled trial N/V from chemotherapy 105; EA at P6 63%, complete relief, at least 8 h Yes (metoclopramide; prednisolone) 2C
    [25] CT N/V from chemotherapy 43; 38 10 Hz EA; 5 sham (crossover subset) 8-10 h relief; 32 patients had complete relief Yes (antiemetics) 2C
    [33] CT N/V from chemotherapy 18; 18 acupressure bands; 18 (crossover study-incorrect placement of acupressure bands) Effective for N/V Yes (antiemetics: prochlorperazine,metoclopramide, and domperidonesuppository) 2C
    [29] Nonconsecutive case series N/V from chemotherapy 26; 26 acupuncture; 51 historical controls-no acupuncture Meanno. of episodes and duration of N/V reduced Yes (metoclopramide,dexamethasone,and diphenhydramine) 3iiiC
    [24] Nonconsecutive case series (pilot study) N/V from chemotherapy 15; 15 EA; none 12 patients-no symptoms for 8 h Yes (antiemetic: metoclopramide) 3iiiC
    [28,30] Consecutive case study N/V from chemotherapy 40; 40 acupressure 8-24 h relief Yes (not specified) 3iiC
    [42] Consecutive, uncontrolled case series N/V from chemotherapy mean no. of emesis 7-3 27; no controls 10 patients had complete response to EA and had no vomiting Yes (antiemetics: either ondansetron 8 mg or granisetron 3 mg) 3iiiC
    1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12
    1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12
    Next Article:

    Today on WebMD

    man holding lung xray
    What you need to know.
    stem cells
    How they work for blood cancers.
     
    woman wearing pink ribbon
    Separate fact from fiction.
    Colorectal cancer cells
    Symptoms, screening tests, and more.
     
    Jennifer Goodman Linn self-portrait
    Blog
    what is your cancer risk
    HEALTH CHECK
     
    colorectal cancer treatment advances
    Video
    breast cancer overview slideshow
    SLIDESHOW
     
    prostate cancer overview
    SLIDESHOW
    lung cancer overview slideshow
    SLIDESHOW
     
    ovarian cancer overview slideshow
    SLIDESHOW
    Actor Michael Douglas
    Article